Godavari Drugs Hits 52-Week Low at Rs. 78.91 Amid Market Decline

Godavari Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs. 78.91 today, October 13, 2025. This decline marks a significant downturn for the stock, which has seen a performance drop of 34.35% over the past year, contrasting sharply with the Sensex's modest gain of 1.10% during the same period.
The stock's recent performance has been characterized by a trend reversal, gaining after five consecutive days of decline. However, it continues to trade below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating persistent weakness in its price momentum.

In terms of financial health, Godavari Drugs has reported negative results for the last three consecutive quarters, with a notable decline in both profit after tax and net sales. The company's ability to service its debt is also a concern, reflected in a high Debt to EBITDA ratio of 3.27 times. Despite these challenges, the stock is trading at a discount compared to its peers' average historical valuations, with a return on capital employed (ROCE) of 11.7%.